CAM 833 a selective orthosteric inhibitor of the BRCA2-RAD51 interaction (Kdof 366 nM; IC50 of 6 μM). CAM 833 has no significant off-target interactions when screened at 10 μM in the Cerep ExpresSPanel. It inhibits DNA recombinase RAD51-mediated homologous recombination through binding to RAD51 at the same site as the BRCA2 FxxA motif. In cells, CAM 833 suppresses the assembly of RAD51 into damage-induced filaments at the sites of DNA damage. CAM 833 potentiates radiation-induced cytotoxicity and poly-ADP ribose polymerase(PARP)1 inhibitor-induced growth suppression in BRCA2-wild-type cells. The product is metabolically stable, does not significantly inhibit CYP450 enzymes, and is suitable forin vivoinvestigation.

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years